home / stock / glaxf / glaxf news


GLAXF News and Press, GlaxoSmithKline Plc From 11/04/20

Stock Information

Company Name: GlaxoSmithKline Plc
Stock Symbol: GLAXF
Market: OTC
Website: gsk.com

Menu

GLAXF GLAXF Quote GLAXF Short GLAXF News GLAXF Articles GLAXF Message Board
Get GLAXF Alerts

News, Short Squeeze, Breakout and More Instantly...

GLAXF - Innoviva: Only For Short-Term Traders

Projecting Innoviva's earnings is pretty easy. For professional investors, it's even easier. Yet the stock fluctuates like crazy, and often, the highest volatility comes when earnings have just been revealed. The sometimes evident disconnect between market action and certain funda...

GLAXF - Compass Therapeutics Starts Plan For $50 Million IPO

Compass Therapeutics has filed to raise $50 million in an IPO. The firm is advancing programs to treat various cancers, including Her2+ breast cancer. CMPX has produced intriguing results in preclinical studies for its lead candidate. For further details see: Compass The...

GLAXF - GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q3 2020 Results - Earnings Call Transcript

GlaxoSmithKline PLC (GSK) Q3 2020 Earnings Conference Call October 28, 2020 10:00 AM ET Company Participants Sarah Elton-Farr - Head of Investor Relations Emma Walmsley - Chief Executive Officer Iain Mackay - Chief Financial Officer Luke Miels - President, Global Pharmaceuticals David Redfern...

GLAXF - GlaxoSmithKline plc 2020 Q3 - Results - Earnings Call Presentation

The following slide deck was published by GlaxoSmithKline plc in conjunction with their 2020 Q3 earnings call. For further details see: GlaxoSmithKline plc 2020 Q3 - Results - Earnings Call Presentation

GLAXF - Tracking John Rogers' Ariel Investments Portfolio - Q2 2020 Update

This article is part of a series that provides an ongoing analysis of the changes made to Ariel Investments’ 13F stock portfolio on a quarterly basis. It is based on Ariel Investments’ regulatory 13F Form filed on 08/14/2020. John Rogers’ 13F portfolio value increased ~1...

GLAXF - Reality Check For COVID Vaccines: Caution Moderna, BioNTech, Novavax

Source: abc news Vaccines take time to develop because they need to be very safe and also effective. It comes as no surprise (especially for coronavirus vaccine development) that the path to development will involve some findings that need careful consideration. Hence news that the AstraZe...

GLAXF - 9 Reasons Why The Race For Major COVID-19 Vaccine Revenues Has Greatly Narrowed

One of my investments is in a small COVID vaccine company, Heat Biologics ( HTBX ), and I generally route for the little guy. So I don't particularly like writing an article that has a number of facts and reasons why probably none of the remaining small players are going to become major player...

GLAXF - GlaxoSmithKline: Quality 5% Dividend Yield Backed By Diversified Asset Portfolio

GlaxoSmithKline plc ( GSK ), with a market cap of $103 billion, is recognized as the world's largest vaccine manufacturer and is currently working on several COVID-19 vaccines. While this area of the business has commanded most of the headlines, GSK has a broader immunology portfolio and tre...

GLAXF - Tracking Tweedy Browne Portfolio - Q2 2020 Update

This article is part of a series that provides an ongoing analysis of the changes made to Tweedy Browne’s 13F portfolio on a quarterly basis. It is based on Tweedy Browne’s regulatory 13F Form filed on 08/11/2020. Please visit our Tracking Tweedy Browne Portfolio series to ge...

GLAXF - 33 Fit Dividend Stocks For Our Times: The August Assortment

Foreword This article is based on five Kiplinger investing articles, plus one from Barron's Weekly, aimed at survival qualities endemic to our times: Pros' Picks: The 15 Best Nasdaq Stocks , by Dan Burrows, published 5/13/20, "screened the Nasdaq Composite for stocks followed by a m...

Previous 10 Next 10